NCT04755569

Brief Summary

The objective of the ODOCOR II CCM lead study is to evaluate the safety and useability of the ODOCOR II intra-cardiac lead specifically intended to deliver CCM as an accessory lead to the Optimizer IPG.

Trial Health

47
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2021

Longer than P75 for all trials

Geographic Reach
3 countries

40 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 11, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 16, 2021

Completed
13 days until next milestone

Study Start

First participant enrolled

March 1, 2021

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

August 2, 2023

Status Verified

August 1, 2023

Enrollment Period

3.8 years

First QC Date

February 11, 2021

Last Update Submit

August 1, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • Primary Safety endpoint

    The primary safety endpoint is the incidence of lead-related complication free rate at 12 months post-index implantation procedure compared to the incidence previously described in the literature for pacing therapy leads.

    12 months

  • Primary Efficacy endpoint

    The total amount of CCM delivered to the cardiac tissue of the right ventricle (measured by CCM percentage) will be measured over a period of 12 months.

    12 month

Secondary Outcomes (2)

  • Secondary Safety endpoint

    12 month

  • Secondary Efficacy endpoint

    12 month

Other Outcomes (1)

  • Additional Endpoints

    at implant

Interventions

ODOCOR II CCM LEADS Implantation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The total investigation is expected to last approximately 3 years , including enrollment and follow-up periods. Four hundred (400) ODOCOR II CCM leads will be implanted in 200 eligible subjects from up to 40 sites in Europe

You may qualify if:

  • Patient signed and dated informed consent form
  • Male or non-pregnant female, aged 18 or older
  • Left ventricular ejection fraction of 25-45% (inclusive)
  • Diagnosed with NYHA Class III or IV heart failure
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Medically stable and with no significant mental illness in the judgement of the principal investigator

You may not qualify if:

  • Infiltrative or inflammatory cardiomyopathy (e.g. amyloid, hemochromatosis, myocarditis, hypertrophic cardiomyopathy, Fabry's disease, cardiac tumor)
  • Primary heart failure due to uncorrected mitral valve disease, or mitral valve repair or clip within 3 months of the baseline testing visit.
  • IV inotropes, hemofiltration, or any form of positive inotropic support within 30 days before the baseline testing visit, including continuous IV inotrope therapy
  • Myocardial infarction within 3 months of the baseline testing visit.
  • Undergone a CABG procedure within 3 months90 days or a PTCA procedure within 30 days of the baseline testing visit.
  • Undergone a cardiac ablation procedure within 90 days prior to consent.
  • Prior heart transplant or ventricular assist device
  • Mechanical tricuspid valve
  • Receiving cardiac resynchronization therapy (CRT) or indicated for Class I CRT implantation according to the ACCF/AHA/HRS guidelines for device-based therapy
  • Currently on dialysis
  • Currently undergoing active chemotherapeutic and/or radiation treatment for cancer
  • Participating in another cardiac investigational device study at the same time
  • Patient is in a vulnerable population (such as significant mental disability, prisoner) that in the judgement of the PI impedes ability to provide informed content.
  • Expected lifespan of less than 12 months from time the baseline testing visit.
  • Resting heart rate \>110 bpm at the time of the baseline testing visit
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (40)

Klinik am Plattenwald

Heilbronn, Baden-Wurttemberg, 74177, Germany

WITHDRAWN

St. Anna Krankenhaus

Sulzbach-Rosenberg, Bavaria, 92237, Germany

RECRUITING

St. Josefs-Hospital Wiesbaden GmbH

Wiesbaden, Hesse, 65189, Germany

WITHDRAWN

Elbe Klinikum Stade

Stade, Lower Saxony, 21682, Germany

WITHDRAWN

Augusta-Kranken-Anstalt Bochum-Mitte

Bochum, North Rhine-Westphalia, 44791, Germany

RECRUITING

Krankenhaus Marie-Hilf Stadtlohn

Stadtlohn, North Rhine-Westphalia, 48703, Germany

RECRUITING

Herzzentrum Dresden

Dresden, Saxony, 01307, Germany

WITHDRAWN

Klinikum Magdeburg

Magdeburg, Saxony-Anhalt, 39120, Germany

WITHDRAWN

DRK Kliniken Berlin Koepenick

Berlin, 12559, Germany

RECRUITING

Charité Berlin Campus Virchow

Berlin, 13353, Germany

RECRUITING

Evangelisches Klinikum Bethel

Bielefeld, 33617, Germany

RECRUITING

Regiomed Kliniken-Coburg

Coburg, Germany

RECRUITING

SRH Krankenhaus Waltershausen-Friedrichroda

Friedrichroda, 99894, Germany

RECRUITING

Marienhospital

Gelsenkirchen, 45886, Germany

RECRUITING

Asklepios Klinik St. Georg

Hamburg, 20099, Germany

RECRUITING

Schoen Klinik Hamburg Eilbek

Hamburg, 22081, Germany

RECRUITING

Evangelisches Krankenhaus Herne

Herne, 44623, Germany

RECRUITING

St. Marien-Hospital Klinikum Luenen

Lünen, D-44534, Germany

NOT YET RECRUITING

Universitaetsklinikum UMM

Mannheim, Germany

RECRUITING

Niels-Stensen-Kliniken Marienhospital Osnabrück GmbH

Osnabrück, 49074, Germany

WITHDRAWN

Azienda Ospedaliera Dei Colli-Monaldi

Naples, Campania, 80131, Italy

RECRUITING

Ospedale "Sacra Famiglia" - Fatebenefratelli dell'

Erba, Lombardo Veneta, 22036, Italy

RECRUITING

Ente Ecclesiastico Ospedale Generale Regionale "F.Miulli" Cardiologia e U.T.I.C.

Acquaviva delle Fonti, Italy

RECRUITING

Ospedale C. e G. "Mazzoni"

Ascoli Piceno, 63100, Italy

RECRUITING

Ospedale San Paolo, UOC Cardiologia ed UTIC

Bari, 70123, Italy

RECRUITING

Azienda Ospedaliero Universitaria Consorziale - Policlinico di Bari U.O.C Cardiologia Ospedaliera

Bari, Italy

RECRUITING

IRCCS Policlinico Sant'Orsola-Malpighi

Bologna, Italy

RECRUITING

Azienda Ospedaliero-Universitaria di Cagliari

Cagliari, Italy

RECRUITING

Azienda Sanitaria Provinciale di Cosenza "Ospedale di Castrovillari

Castrovillari, Italy

RECRUITING

ASL TO 4 - Presidio Ospedaliero Riunito sede di Cirie

Cirié, Italy

RECRUITING

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, 20122, Italy

RECRUITING

Azienda Ospedaliera Universitaria Maggiore della Carita

Novara, 28100, Italy

RECRUITING

Gruppo Synergo - Casa Di Cura Pierangeli

Pescara, 65124, Italy

RECRUITING

Presidio Ospedaliero Sant'Andrea

Vercelli, 13100, Italy

RECRUITING

Ospedale San Bortolo di Vicenza - Azienda UlSS 8 Berica

Vicenza, 36100, Italy

RECRUITING

Complejo Hospitario Torrecardenas

Almería, 04009, Spain

RECRUITING

Hospital Virgen de las Nieves

Granada, 18014, Spain

RECRUITING

Hospital 12 de Octubre

Madrid, 28041, Spain

RECRUITING

Hospital Puerta de Hierro

Madrid, 28222, Spain

RECRUITING

Hospital Clinico U. de Santiago

Santiago de Compostela, 15706, Spain

RECRUITING

Study Officials

  • Stefano DeVivo, MD

    Monaldi Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 11, 2021

First Posted

February 16, 2021

Study Start

March 1, 2021

Primary Completion

December 31, 2024

Study Completion

December 31, 2025

Last Updated

August 2, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations